Condition: Emotional Processing · Cognition · Mood Disorders · Sponsor: University of Oxford
The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information. Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.
This description comes directly from the study's public registry record.
Marieke AG Martens, DPhil · +441865 618338 · marieke.martens@psych.ox.ac.uk
Catherine J Harmer, DPhil · +441865 618326 · catherine.harmer@psych.ox.ac.uk
Always discuss trial participation with your own doctor first.
| University of Oxford, Department of Psychiatry | Oxford, Oxfordshire, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06412315